logo
explain how to read the page

The above diagram shows the color scheme of the layout in the main result page. The parent entities and officers are those entities, including individual and legal persons, have significant controls over the company in focus. The offspring entities and appointments are those entities that the company in focus can influence on.

Clicking the links on parent entities or officers, and offspring entities or managed companies will put them in focus and show upstream or downstream connections. In general, ascendant entities can be found by moving toward upstream, and descendant entities are by toward downstream. In this way, progenitor entities such as grandparent companies (parents of parent), sibling companies (children of parent), partner companies (parents of child), and progeny entities such as grandchild companies (children of child) can be found easily.

Parent entities and officers
Active 3
  • 1
    Smit, Alwyn Jacobus Nicolaas
    Born in January 1961
    Individual (10 offsprings)
    Officer
    icon of calendar 2020-07-27 ~ now
    OF - Director → CIF 0
  • 2
    Nichol, Karen Yvonne
    Born in June 1967
    Individual (6 offsprings)
    Officer
    icon of calendar 2020-07-27 ~ now
    OF - Director → CIF 0
  • 3
    icon of addressCentral Pharma Caxton Road, Elm Farm Industrial Estate, Bedford, Bedfordshire
    Active Corporate (4 parents, 4 offsprings)
    Profit/Loss (Company account)
    -108,199 GBP2024-01-01 ~ 2024-12-31
    Person with significant control
    icon of calendar 2020-07-27 ~ now
    PE - Ownership of shares – 75% or more → CIF 0
    PE - Ownership of voting rights - 75% or more → CIF 0
parent relation
Company in focus

CENTRAL PHARMA CELL AND GENE THERAPY LTD

Standard Industrial Classification
82920 - Packaging Activities
74909 - Other Professional, Scientific And Technical Activities N.e.c.
Brief company account
Turnover/Revenue
512,809 GBP2024-01-01 ~ 2024-12-31
741,361 GBP2023-01-01 ~ 2023-12-31
Cost of Sales
-45,891 GBP2024-01-01 ~ 2024-12-31
-47,776 GBP2023-01-01 ~ 2023-12-31
Gross Profit/Loss
466,918 GBP2024-01-01 ~ 2024-12-31
693,585 GBP2023-01-01 ~ 2023-12-31
Administrative Expenses
-758,164 GBP2024-01-01 ~ 2024-12-31
-679,138 GBP2023-01-01 ~ 2023-12-31
Operating Profit/Loss
-291,246 GBP2024-01-01 ~ 2024-12-31
14,447 GBP2023-01-01 ~ 2023-12-31
Interest Payable/Similar Charges (Finance Costs)
-399 GBP2024-01-01 ~ 2024-12-31
-13,069 GBP2023-01-01 ~ 2023-12-31
Profit/Loss on Ordinary Activities Before Tax
-291,645 GBP2024-01-01 ~ 2024-12-31
1,378 GBP2023-01-01 ~ 2023-12-31
Profit/Loss
-291,645 GBP2024-01-01 ~ 2024-12-31
1,378 GBP2023-01-01 ~ 2023-12-31
Property, Plant & Equipment
23,763 GBP2024-12-31
39,496 GBP2023-12-31
Debtors
122,798 GBP2024-12-31
189,897 GBP2023-12-31
Cash at bank and in hand
3,527 GBP2024-12-31
62,288 GBP2023-12-31
Current Assets
126,325 GBP2024-12-31
252,185 GBP2023-12-31
Net Current Assets/Liabilities
-2,036,923 GBP2024-12-31
-1,914,282 GBP2023-12-31
Total Assets Less Current Liabilities
-2,013,160 GBP2024-12-31
-1,874,786 GBP2023-12-31
Creditors
Non-current
-153,271 GBP2024-12-31
Net Assets/Liabilities
-2,166,431 GBP2024-12-31
-1,874,786 GBP2023-12-31
Equity
Called up share capital
1 GBP2024-12-31
1 GBP2023-12-31
1 GBP2022-12-31
Retained earnings (accumulated losses)
-2,166,432 GBP2024-12-31
-1,874,787 GBP2023-12-31
-1,876,165 GBP2022-12-31
Equity
-2,166,431 GBP2024-12-31
-1,874,786 GBP2023-12-31
-1,876,164 GBP2022-12-31
Comprehensive Income/Expense
Retained earnings (accumulated losses)
-291,645 GBP2024-01-01 ~ 2024-12-31
1,378 GBP2023-01-01 ~ 2023-12-31
Comprehensive Income/Expense
-291,645 GBP2024-01-01 ~ 2024-12-31
1,378 GBP2023-01-01 ~ 2023-12-31
Average Number of Employees
32024-01-01 ~ 2024-12-31
32023-01-01 ~ 2023-12-31
Property, Plant & Equipment - Depreciation Expense
Owned assets
15,733 GBP2024-01-01 ~ 2024-12-31
16,317 GBP2023-01-01 ~ 2023-12-31
Property, Plant & Equipment - Gross Cost
Plant and equipment
73,261 GBP2023-12-31
Property, Plant & Equipment - Accumulated Depreciation & Impairment
Plant and equipment
49,498 GBP2024-12-31
33,765 GBP2023-12-31
Property, Plant & Equipment - Increase From Depreciation Charge for Year
Plant and equipment
15,733 GBP2024-01-01 ~ 2024-12-31
Property, Plant & Equipment
Plant and equipment
23,763 GBP2024-12-31
39,496 GBP2023-12-31
Trade Debtors/Trade Receivables
Current, Amounts falling due within one year
39,101 GBP2024-12-31
161,152 GBP2023-12-31
Amounts Owed by Group Undertakings
Current
12,012 GBP2024-12-31
Other Debtors
Current, Amounts falling due within one year
71,685 GBP2024-12-31
28,745 GBP2023-12-31
Debtors
Current, Amounts falling due within one year
122,798 GBP2024-12-31
189,897 GBP2023-12-31
Trade Creditors/Trade Payables
Current
527,970 GBP2024-12-31
335,141 GBP2023-12-31
Amounts owed to group undertakings
Current
1,527,959 GBP2024-12-31
1,711,119 GBP2023-12-31
Other Taxation & Social Security Payable
Current
14,240 GBP2024-12-31
30,370 GBP2023-12-31
Other Creditors
Current
93,079 GBP2024-12-31
89,837 GBP2023-12-31
Non-current
153,271 GBP2024-12-31
  • CENTRAL PHARMA CELL AND GENE THERAPY LTD
    Info
    Registered number 12769240
    icon of addressCentral Pharma Caxton Road, Elm Farm Ind Estate, Bedford MK41 0HT
    PRIVATE LIMITED COMPANY incorporated on 2020-07-27 (5 years 5 months). The company status is Active.
    The last date of confirmation statement was made at 2025-01-04
    CIF 0
child relation
Offspring entities and appointments
Active 0
  • Not found in our database.

qrcode

Privacy notice

Terms and conditions

The content of this website is protected by AgonGuard.

© 2022- Polylogarithmic Technology Ltd (Registered in England and Wales No. 14256313). All rights reserved.

Contains public sector information retrieved at 12 November 2025 and licensed under the Open Government Licence v3.0.